Aardvark Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AARD Nasdaq 2836 aardvarktherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aardvark Therapeutics, Inc.

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Dec 23rd, 2025 7:33 am
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Dec 11th, 2025 2:27 pm
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome - Dec 10th, 2025 2:05 pm
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - Nov 25th, 2025 2:05 pm
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates - Nov 13th, 2025 2:05 pm
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - Nov 11th, 2025 2:05 pm
Datadog, Trade Desk upgraded: Wall Street's top analyst calls - Nov 7th, 2025 7:33 am
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 - Nov 4th, 2025 10:00 am
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Nov 3rd, 2025 3:55 pm
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November - Nov 3rd, 2025 6:00 am
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek - Oct 22nd, 2025 6:00 am
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment - Oct 17th, 2025 7:27 am
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - Oct 8th, 2025 6:00 am
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum - Sep 23rd, 2025 2:05 pm
MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug - Sep 22nd, 2025 6:01 am
Insider Stock Buying Reaches US$730.4k On Aardvark Therapeutics - Sep 22nd, 2025 4:43 am
LB Pharmaceuticals raises $285 million in US IPO - Sep 10th, 2025 7:23 pm
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought - Sep 8th, 2025 8:41 am
2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher Upside - Sep 2nd, 2025 5:30 am
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September - Aug 27th, 2025 2:10 pm